"Using your example figures of $32m @ 10% this seems to line up...

"Using your example figures of $32m @ 10% this seems to line up reasonably with ADO being cashflow positive."

Unfortunately, they are not my figures Ds.
My figures are 5% of 10 million, which is about 500k a year.
32 million in the estimated total ebioscience revenue for it its FlowCymetry products.
The ebio ceo and president at the time inferred that they will use messngo for their FlowCytomix™ Bead-based immunoassays.
I think I am generous in assuming one third of 32 million and even if there is 10% royalty that you assume(which I don't) that only adds up to 1 mil a year. Hardly cash flow positive.
Now, I remember Ds, somewhere in the past you wished to make a bet with me.
Are you willing to bet that their revenue solely from Ebio and affemetrix will make them cash positive by calendar year ending 2013?